Jianmin Pharmaceutical Group Co Ltd (600976) - Total Liabilities
Based on the latest financial reports, Jianmin Pharmaceutical Group Co Ltd (600976) has total liabilities worth CN¥1.74 Billion CNY (≈ $254.23 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Jianmin Pharmaceutical Group Co Ltd to assess how effectively this company generates cash.
Jianmin Pharmaceutical Group Co Ltd - Total Liabilities Trend (2001–2024)
This chart illustrates how Jianmin Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Jianmin Pharmaceutical Group Co Ltd to evaluate the company's liquid asset resilience ratio.
Jianmin Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jianmin Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Energisa Mato Grosso - Distribuidora de Energia S/A
SA:ENMT3
|
Brazil | R$11.53 Billion |
|
Gerresheimer AG
F:GXI
|
Germany | €3.29 Billion |
|
Mediterranean Towers Ltd
TA:MDTR
|
Israel | ILA5.14 Billion |
|
Shenandoah Telecommunications Co
NASDAQ:SHEN
|
USA | $870.79 Million |
|
Alltop Technology Co Ltd
TWO:3526
|
Taiwan | NT$3.67 Billion |
|
LSI Industries Inc
NASDAQ:LYTS
|
USA | $148.21 Million |
Liability Composition Analysis (2001–2024)
This chart breaks down Jianmin Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Jianmin Pharmaceutical Group Co Ltd (600976) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.59 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.40 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jianmin Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jianmin Pharmaceutical Group Co Ltd (2001–2024)
The table below shows the annual total liabilities of Jianmin Pharmaceutical Group Co Ltd from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.83 Billion ≈ $267.39 Million |
-4.40% |
| 2023-12-31 | CN¥1.91 Billion ≈ $279.71 Million |
+21.76% |
| 2022-12-31 | CN¥1.57 Billion ≈ $229.71 Million |
+24.85% |
| 2021-12-31 | CN¥1.26 Billion ≈ $183.99 Million |
+14.94% |
| 2020-12-31 | CN¥1.09 Billion ≈ $160.07 Million |
+51.80% |
| 2019-12-31 | CN¥720.63 Million ≈ $105.45 Million |
+24.87% |
| 2018-12-31 | CN¥577.11 Million ≈ $84.45 Million |
-29.34% |
| 2017-12-31 | CN¥816.71 Million ≈ $119.51 Million |
+5.18% |
| 2016-12-31 | CN¥776.45 Million ≈ $113.62 Million |
+28.40% |
| 2015-12-31 | CN¥604.72 Million ≈ $88.49 Million |
+11.00% |
| 2014-12-31 | CN¥544.79 Million ≈ $79.72 Million |
+7.90% |
| 2013-12-31 | CN¥504.92 Million ≈ $73.89 Million |
+41.08% |
| 2012-12-31 | CN¥357.90 Million ≈ $52.37 Million |
+22.87% |
| 2011-12-31 | CN¥291.28 Million ≈ $42.62 Million |
+27.32% |
| 2010-12-31 | CN¥228.78 Million ≈ $33.48 Million |
-51.91% |
| 2009-12-31 | CN¥475.79 Million ≈ $69.62 Million |
+19.61% |
| 2008-12-31 | CN¥397.80 Million ≈ $58.21 Million |
+178.04% |
| 2007-12-31 | CN¥143.07 Million ≈ $20.94 Million |
-49.83% |
| 2006-12-31 | CN¥285.18 Million ≈ $41.73 Million |
-5.36% |
| 2005-12-31 | CN¥301.33 Million ≈ $44.09 Million |
+37.36% |
| 2004-12-31 | CN¥219.38 Million ≈ $32.10 Million |
-9.46% |
| 2003-12-31 | CN¥242.31 Million ≈ $35.46 Million |
+25.34% |
| 2002-12-31 | CN¥193.32 Million ≈ $28.29 Million |
+17.27% |
| 2001-12-31 | CN¥164.85 Million ≈ $24.12 Million |
-- |
About Jianmin Pharmaceutical Group Co Ltd
Jianmin Pharmaceutical Group Co.,Ltd. manufactures and sells medicines in China. It provides medicines and pediatric drugs under the Jianmin, Longmu, and Yekaitai brand name. The company provides OTC, medical, and general health products, as well as consultation service. Jianmin Pharmaceutical Group Co.,Ltd. was founded in 1993 and is headquartered in Wuhan, China.